VI4 Archives
Stomach bug hit-and-run
Jul. 23, 2020—The H. pylori machinery that “injects” an oncoprotein into stomach cells contributes to the development of gastric cancer, Vanderbilt researchers demonstrate.
Cellular antiviral defenses
Jul. 23, 2020—A cellular RNA quality control mechanism was known to restrict replication of RNA viruses. Vanderbilt researchers have discovered it is also antiviral against DNA viruses.
“Nur” target may aid arthritis treatment
Jul. 13, 2020—Vanderbilt immunologists have discovered that the protein Nur77 is part of a control mechanism that guards against autoimmunity in natural killer T cells.
Recurrent UTIs linked to hidden reservoir
Jul. 9, 2020—Bacterial invasion of vaginal cells sets up a protective niche and a reservoir for recurrent urinary tract infections, Vanderbilt researchers demonstrated.
VUMC’s Byndloss recognized for microbiome research
Jul. 9, 2020—Mariana Byndloss, DVM, PhD, assistant professor of Pathology, Microbiology and Immunology, has been selected as a runner-up of the inaugural NOSTER & Science Microbiome Prize.
New space bolsters infectious disease and immunology discovery
Jul. 9, 2020—The Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) recently moved into its new research and administrative home.
Vanderbilt Institute for Infection, Immunology and Inflammation holds third annual symposium
Jun. 24, 2020—The Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) held its third annual symposium last week as a virtual, on-line event to preserve social distancing during COVID-19.
C. diff captures blood cell cofactor to build defensive shield
Jun. 10, 2020—Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics.
Study explores how staph bacteria can survive in bone
Jun. 3, 2020—A comprehensive evaluation of the metabolic pathways that support Staphylococcus aureus (“staph”) growth during invasive bone infections could offer new targets for treatment.
The adaptable anthrax bacterium
May. 14, 2020—Vanderbilt researchers discover how anthrax bacterium defends itself against structural damage and resists the toxicity of the antimicrobial drug targocil.
Looking through MudPIT for protein interactions
Feb. 25, 2020—The identification of novel protein interactions and sites of modification in proteins involved in mRNA translation adds to understanding of a process that is an important therapeutic target.
Allergic diseases expert Locksley set for Discovery Lecture
Feb. 12, 2020—Richard Locksley, MD, director of the Sandler Asthma Basic Research Center at the University of California, San Francisco, will deliver the next Flexner Discovery Lecture on Thursday, Feb. 20.
